Invention Grant
- Patent Title: Membrane-anchoring and apoptosis-inducing fusion protein comprising a fragment of TRAIL and CD40L and encoding polynucleotides
-
Application No.: US15304282Application Date: 2015-04-15
-
Publication No.: US10370422B2Publication Date: 2019-08-06
- Inventor: Daniel Palmer , Taha Elmitwalli
- Applicant: The University of Liverpool
- Applicant Address: GB Liverpool
- Assignee: The University of Liverpool
- Current Assignee: The University of Liverpool
- Current Assignee Address: GB Liverpool
- Agency: Faegre Baker Daniels LLP
- Priority: GB1406705.2 20140415
- International Application: PCT/GB2015/051145 WO 20150415
- International Announcement: WO2015/159079 WO 20151022
- Main IPC: C07K14/52
- IPC: C07K14/52 ; C07K19/00 ; C12N15/11 ; C07K14/47 ; C07K14/705

Abstract:
Provided are compositions comprising fusion proteins, polynucleotides and/or expression vectors with therapeutic utility for suppressing and/or treating cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.
Public/Granted literature
- US20170044226A1 FUSION PROTEINS, POLYNUCLEOTIDES, EXPRESSION VECTORS, AND THEIR USES Public/Granted day:2017-02-16
Information query